CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Sep. 30, 2022		44,680,000
Beginning balance at Sep. 30, 2022	$ 170,979	$ 44	$ 216,493	$ (28,219)	$ (17,339)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		86,000
Exercise of stock options	676		676
Settlement of restricted stock units (in shares)		572,000
Settlement of restricted stock units	0	$ 1	(1)
Issuance of common stock under employee stock purchase plan (in shares)		71,000
Issuance of common stock under employee stock purchase plan	619		619
Stock-based compensation expense	5,146		5,146
Components of comprehensive income (loss):
Net income (loss)	9,899				9,899
Currency translation adjustment	15,725			15,725
Change in unrealized gain (loss) on investments	648			648
Ending balance (in shares) at Mar. 31, 2023		45,409,000
Ending balance at Mar. 31, 2023	203,692	$ 45	222,933	(11,846)	(7,440)
Beginning balance (in shares) at Dec. 31, 2022		45,249,000
Beginning balance at Dec. 31, 2022	191,868	$ 45	219,596	(15,164)	(12,609)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		3,000
Exercise of stock options	14		14
Settlement of restricted stock units (in shares)		86,000
Settlement of restricted stock units	0
Issuance of common stock under employee stock purchase plan (in shares)		71,000
Issuance of common stock under employee stock purchase plan	619		619
Stock-based compensation expense	2,704		2,704
Components of comprehensive income (loss):
Net income (loss)	5,169				5,169
Currency translation adjustment	3,022			3,022
Change in unrealized gain (loss) on investments	296			296
Ending balance (in shares) at Mar. 31, 2023		45,409,000
Ending balance at Mar. 31, 2023	$ 203,692	$ 45	222,933	(11,846)	(7,440)
Beginning balance (in shares) at Sep. 30, 2023	45,591,199	45,591,000
Beginning balance at Sep. 30, 2023	$ 205,188	$ 46	228,691	(14,237)	(9,312)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	166,634	167,000
Exercise of stock options	$ 1,042		1,042
Settlement of restricted stock units (in shares)		722,000
Settlement of restricted stock units	0	$ 1	(1)
Acquisition-related shares issued (in shares)		311,000
Acquisition-related shares issued	3,471		3,471
Stock-based compensation expense	7,318		7,318
Components of comprehensive income (loss):
Net income (loss)	(5,511)				(5,511)
Currency translation adjustment	4,578			4,578
Change in unrealized gain (loss) on investments	$ 60			60
Ending balance (in shares) at Mar. 31, 2024	46,790,611	46,791,000
Ending balance at Mar. 31, 2024	$ 216,146	$ 47	240,521	(9,599)	(14,823)
Beginning balance (in shares) at Dec. 31, 2023		46,632,000
Beginning balance at Dec. 31, 2023	213,798	$ 47	236,447	(7,591)	(15,105)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		71,000
Exercise of stock options	186		186
Settlement of restricted stock units (in shares)		88,000
Settlement of restricted stock units	0
Stock-based compensation expense	3,888		3,888
Components of comprehensive income (loss):
Net income (loss)	282				282
Currency translation adjustment	(1,966)			(1,966)
Change in unrealized gain (loss) on investments	$ (42)			(42)
Ending balance (in shares) at Mar. 31, 2024	46,790,611	46,791,000
Ending balance at Mar. 31, 2024	$ 216,146	$ 47	$ 240,521	$ (9,599)	$ (14,823)